Psychiatry AtlasMedication guide · United States

Diabetes medicine also used off-label for antipsychotic-related weight gain

Metformin (Glucophage, Glucophage XR)

Generic name
metformin hydrochloride
Brand names
Glucophage; Glucophage XR
Medication class
Diabetes medicine also used off-label for antipsychotic-related weight gain
Forms covered
Laurus metformin hydrochloride immediate-release tablets; Laurus metformin hydrochloride extended-release tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

FDA Boxed Warning

Laurus metformin hydrochloride immediate-release tablets; Laurus metformin hydrochloride extended-release tablets.

Metformin-associated lactic acidosis can be fatal. Risk increases with kidney impairment, low-oxygen illness, excessive alcohol, liver or mitochondrial disease, certain interacting medicines and some procedures. Suspected lactic acidosis requires stopping metformin and urgent hospital treatment.

Metformin treats type 2 diabetes and is also used off-label to prevent or manage weight gain associated with antipsychotic treatment. Kidney function and its boxed warning about lactic acidosis are central to safe use.

Glucophage (historical brand); Glucophage XR (historical brand).

What to expect: For off-label weight management, the aim may be slowing further gain or achieving a modest reduction; weight loss is not guaranteed.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Glucose control in type 2 diabetes — Adults and children aged 10 years and older. Adjunct to diet and exercise; this selected immediate-release label has the pediatric scope.Laurus metformin hydrochloride immediate-release tablets.
  • Glucose control in type 2 diabetes — Adults. The selected Laurus ER label is adult-only; other products may differ.Laurus metformin hydrochloride extended-release tablets.

Other uses (off-label)

Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.

  • Prevention or management of antipsychotic-associated weight gain — Patients selected after clinician assessment; evidence and guideline populations vary. Meaningful evidence and guideline support, but not FDA-approved for this purpose and not an antipsychotic replacement.Laurus metformin hydrochloride immediate-release tablets; Laurus metformin hydrochloride extended-release tablets.

What should I expect?

For off-label weight management, the aim may be slowing further gain or achieving a modest reduction; weight loss is not guaranteed. Progress is assessed over time alongside nutrition, activity and the ongoing need for the antipsychotic.

Stomach symptoms often influence early treatment adjustments. Follow-up also checks kidney function and, during longer treatment, vitamin B12.

How do I take it safely?

Take immediate-release tablets with meals; the covered extended-release product is taken with the evening meal and swallowed whole. Its pediatric approval differs from immediate release. Do not transfer a diabetes dosing schedule into a personal weight-management plan.

Check kidney function before and during treatment. Do not use with severe kidney impairment or metabolic acidosis. Liver disease, low-oxygen illness, dehydration, excessive alcohol and certain mitochondrial diseases increase lactic-acidosis concerns. Discuss pregnancy or breastfeeding; metformin may restore ovulation, allowing pregnancy.

Tell the team before contrast imaging or procedures that restrict food and fluids: a temporary pause and kidney reassessment may be needed. The need and restart timing depend on the procedure and health status. Review topiramate, medicines that reduce metformin clearance and other diabetes treatments.

Long-term treatment needs vitamin B12 assessment when indicated and according to the label’s monitoring schedule. For a missed dose of the selected products, take the next scheduled dose; never double. Illness-related interruptions need clinical advice before restarting.

The covered label calls for annual blood counts and vitamin B12 measurement every two to three years, or sooner when symptoms or risks warrant.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Gastrointestinal upset, including diarrhea, nausea and gas, is common.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • The boxed warning covers lactic acidosis, a dangerous buildup of acid in the blood. Severe weakness, muscle pain, unusual sleepiness, breathing difficulty or abdominal pain can be warning signs. Suspected lactic acidosis requires stopping metformin and immediate hospital assessment.
  • Risk rises with kidney impairment, low oxygen, serious illness, liver or mitochondrial disease, excessive alcohol, certain medicines and some procedures. Contact the clinical team urgently during major dehydration or illness. Collapse, breathing difficulty, altered consciousness or suspected overdose is an emergency.

What else should I know to stay safe?

  • Check kidney function before and during treatment. Do not use with severe kidney impairment, metabolic acidosis or product allergy. Review liver disease, low-oxygen illness, dehydration, excessive alcohol, specified mitochondrial disease and interacting medicines such as topiramate. The label advises against use in mitochondrial diseases such as MELAS or maternally inherited diabetes and deafness (MIDD); tell your clinician if you have either diagnosis.
  • Before iodinated contrast, surgery or procedures restricting food and fluids, ask whether treatment must be paused and kidney function reassessed. Restarting depends on the clinical situation; serious illness or dehydration also needs prompt advice.
  • Monitor blood counts annually and vitamin B12 every two to three years, or sooner when indicated. Other diabetes medicines can increase low-blood-sugar risk. Discuss pregnancy and breastfeeding; restored ovulation can permit pregnancy. The selected extended-release product does not share the immediate-release pediatric approval.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Preventing additional weight gain can be a meaningful result, even when the scale does not fall dramatically.
  • Metformin does not usually cause low blood sugar on its own, but the risk changes when it is combined with insulin or certain other diabetes medicines.
  • Persistent fatigue or numbness deserves review: long-term metformin can lower vitamin B12.

How does it work?

Metformin lowers blood sugar by reducing how much glucose the liver makes and helping the body respond better to insulin. It also reduces some glucose absorption from the gut. Its effect on antipsychotic-associated weight gain is not fully explained by these actions.

Explore medication science

How was this medicine developed?

Glucophage received FDA approval in 1995 for diabetes. Metformin’s later psychiatric role developed from evidence on antipsychotic-associated weight gain; that role remains off-label rather than a separate FDA-approved indication.

How do I say the name?

Metformin: met-FOR-min. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Carolan and colleagues: guideline for prevention of antipsychotic-induced weight gain, published online December 2024
  2. Fitzgerald and colleagues: evidence-based metformin guideline for management of antipsychotic-induced weight gain
  3. Laurus metformin immediate-release and extended-release tablets: US prescribing information, July 2026
  4. Drugs@FDA: Laurus metformin tablets, ANDA209882
  5. Drugs@FDA: Laurus metformin extended-release tablets, ANDA217631
  6. Drugs@FDA: historical Glucophage, NDA020357
  7. Metformin: patient information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?..

  8. Glumetza FDA prescribing information
  9. Metformin: Package Insert / Prescribing Information / MOA
  10. Drugs@FDA: historical Glucophage XR, NDA021202
  11. Metformin: verified neutral parent, PubChem CID 4091
  12. ISMP List of Confused Drug Names
  13. FDA reference prescribing information — Glucophage/Glucophage XR (2018)
  14. Frequently Asked Questions about Labeling for Prescription Medicines | FDA

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top